Intended for healthcare professionals


Anticoagulation may be beneficial in high risk factor V Leiden carriers

BMJ 1998; 317 doi: (Published 08 August 1998) Cite this as: BMJ 1998;317:416
  1. Trevor Baglin, Consultant haematologist,
  2. Caroline Baglin, Clinical nurse specialist,
  3. Karen Brown, Senior technologist,
  4. Roger Luddington, Chief technologist,
  5. East Anglian Thrombophilia Study Group
  1. Clinical Haematology, Box 234, Addenbrooke's NHS Trust, Cambridge CB2 2QQ

    EDITOR—Sarasin and Bounameaux's decision analysis model of treatment in factor V Leiden carriers1 is in keeping with the results of our cohort study.2 In our study the annual rate of recurrence when treatment with warfarin was stopped was 11.1 per 100 patient-years. Patients who had an idiopathic first event were more likely to have a recurrence than those whose first event was precipitated (log rank=4.76, P=0.029). The recurrence …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription